Risankizumab is a drug which is injected into the skin. It works in a unique way by blocking a specific process which allows the body’s immune cells (specifically T-cells) from attacking and damaging the skin. Risankizumab is currently being trialled in a range of diseases involving the immune system including Crohn’s disease, and psoriatic arthritis.
Risankizumab (by Subcutaneous Injection) for Moderate to Severe Chronic Plaque Psoriasis
Interventions:
Risankizumab (BI 655066; Skyrizi; ABBV 066)
Indications:
Plaque psoriasis
Therapeutic Areas:
Dermatology
Year:
2017